=Ab s t r a c t = P u r p o s e: To evaluate the correlation between serum methotrexate (MTX) peak levels and clinical outcome of osteosarcoma, as well as to determine the correlation of these levels with the histologic response and event-free survival (EFS).
).
Re s u l t s: Totally, 204 courses of HD MTX were administered. The serial MTX levels (mean±SE) at 4 h (peak), 24 h, 48 h, and 72 h were 1292.14± 12.83 µM, 9.29±3.89 µM, 1.73±1.37 µM, and 0.58±0.44 µM, respectively. The peak MTX serum level was 1292.14±12.83 µM. Neither the continuous average MTX peak level nor the dichotomized MTX peak level was related to the histologic response. However, the patients with a high 24-h MTX level (3.4 µM) had a poor histologic response (P=0.044). An inverse relationship was observed between MTX levels and survival: the EFS was better in the patients with a mean MTX peak level of less than 1,400 µM (P=0.002) and mean 24-h MTX level of less than 3.4 µM (P=0.011). 
I n t r o d u c t i o n
High dose methotrexate (HD MTX) is one of the major chemotherapeutic agents that are used for treating osteosarcoma 1) . The pharmacokinetics of HD MTX shows individual variability and this is influenced by many factors such as age, the hydration status and the concurrent use of nephrotoxic agents [2] [3] [4] . Individually monitoring the MTX serum levels enables appropriate alteration of the dose of leucovorin so as to avoid potential life threatening toxicities 5, 6) . Several studies have investigated the relationship between the MTX level and the histologic response or the patient outcome. The MTX serum level is supposed to have a linear relationship with tumor necrosis rate; however, inconsistent results have been reported. The earlier studies consistently advocated that a certain threshold MTX level (700 µM or 1,000 µM) must be achieved to attain a good histologic response 5, 7, 8) . However, the subsequent studies reported that the MTX level did not influence the histologic response [9] [10] [11] .
Moreover, a recent study showed contradictory results that patients with very high MTX peak levels (above 1,500 µM) had poor outcome 12) . These results might partly be accounted for by the heterogeneity of the study populations and the chemotherapy protocols of the previous studies. Most of the previous studies have included both localized and metastatic disease. Moreover, the preoperative chemotherapy was not homogeneous with regard to the MTX dose and schedule.
In this retrospective study, we focused on maintaining the homogeneity of the study population; therefore, we selected those patients who met following criteria: 1) they had lo-calized extremity osteosarcoma; 2) they received 2 cycles of neoadjuvant chemotherapy consisted of HD MTX, cisplatin and doxorubicin. We aimed to assess the correlation between the serum MTX levels and histologic response and outcome.
We asked two questions: 1) Is the MTX peak level related to histologic response? If so, does a certain MTX level exist that must be achieved for obtaining a good histologic response? 2) In addition to the peak level, is the MTX excretion rate related to the outcome?
Ma t e r i a l sa n dMe t h o d s
.Pa t i e n tSe l e c t i o n
This was a retrospective study and patients who met the following criteria were eligible. They were: an age less than 40 years, AJCC stage II osteosarcoma 13) , no history of treatment except for biopsy, primary tumor in an extremity, .
.Ch e mo t h e r a p yPr o t o c o l
All the patients underwent two courses of preoperative 
.MT X I n f u s i o na n dAn a l y s i so ft h eMT X L e v e l
The patients were hydrated intravenously with 250 mL/m 2 of 5% glucose together with 100 mol/L NaHCO3 and 20 mL KCl solution one hour before MTX infusion. The MTX was dissolved in 500 mL of D5W and this was infused over 4 hours. After MTX infusion, the patients were hydrated with the same fluid for a total of 1,500 mL/m 2 in the first 24
hours. The urine pH was monitored every 8 hours and the urine was alkalinized with NaHCO3 to a pH≥7. After 24 hours, the intravenous hydration was increased to a rate of 3,000 mL/ m 2 /day. Intravenous leucovorin rescue (15 mg/m2 every 6 hours) was begun 24 hours following the start of MTX infusion and the dose was adjusted according to the serum MTX levels. Venous blood samples were taken at the end of the infusion (the peak value) and then every 24 hours, and the 
.St a t i s t i c a lAn a l y s i s
We assessed the correlations between the MTX levels and the histologic response and event-free survival (EFS). The mean MTX levels according to the clinicopathologic variables were compared using independent Student's t-tests. The patients were divided into two groups using various cut-off values of peak and the 24-hr MTX levels. Chi-square tests were used to compare the histologic response and event in each group and to determine the significant univariate predictors. The event-free interval was defined as the date of diagnosis to the time of the last visit or the date when either metastasis or local recurrence was found. The survival analysis between the MTX levels and event was analyzed by the Kaplan-Meier method, and the difference was calculated with using the log-rank test. All calculations were performed with SPSS version 13.0 software (SPSS Inc, Chicago, IL), and P values<0.05 was considered significant.
Re s u l t s
.Pa t i e n tCh a r a c t e r i s t i c s
The patient's characteristics are summarized in Table 1 .
The median age of the 52 patients was 16 years (range:
4-37 years). The location of tumor was at the distal femur in 22 cases (42.3%), the proximal tibia in 13 cases (25.0%), the proximal humerus in 10 cases (19.2%), the proximal fibula in 2 cases (3.8%) and elsewhere in 5 cases (9.6%).
Fifty-one patients (98.1%) underwent limb salvage surgery, whereas 1 patient (1.9%) had amputation. The median follow-up duration of the 52 patients were 28 months (range: 13-53 months). There were no local recurrences and all the events were metastasis, with 9 cases in lung and 2 cases in bone. Mean event-free interval for the 43 patients who were without subsequent metastasis was 34.3±1.3 months and that for the entire cohort was 30.9±1.6 months.
The 3-year EFS rate of the entire cohort was 84.5±5.1%. 
.T h eMT X Pe a kL e v e l

.Cl i n i c o p a t h o l o g i cCh a r a c t e r i s t i c sAc c o r d i n gt o t h eMT X l e v e l
Using various cutoff values for MTX peak levels, we divided patients into two groups and compared with the histologic response and development of metastasis. None of the above-mentioned peak levels was related to good histologic response. On the contrary, too high peak level was related to poor outcome. Thirteen patients (25%) had achiev-A B Fig. 1 . Event-free survival (EFS) according to the peak and 24-h methotrexate (MTX) levels. (A) The three-year EFS is better in the patients with a mean MTX peak level of less than 1400 µM compared with the patients with a mean MTX peak level of greater than or equal to 1400 µM. (B) The patients with a mean 24-h MTX level of less than 3.4 µM fared better than the patients with a mean 24-h MTX level of greater than or equal to 3.4 µM. Table 2 ).
Unexpectedly, 24-hr MTX level was related to the histologic response. Using various cutoff values for 24-hr MTX levels, we divided patients into two groups and compared its correlation with outcome. Patients with a 24-hr MTX level above the median value of 3.4 µM showed a poor histologic response (P=0.044) and were related to the development of metastasis (P=0.010, Table 2 ).
.Su r v i v a lAn a l y s i sAc c o r d i n gt ot h eMT X l e v e l
The patients were divided into two groups using the cut-off values of the peak and 24-hr MTX levels. The cutoff value 1,400 µM and 3.4 µM were chosen based on the results on Table 2 . An inverse relationship was observed between the MTX levels and survival: 1) The EFS of the patients whose mean MTX peak level <1,400 µM was better than the EFS of the patients with a mean MTX peak level 1,400 µM 
Di s c u s s i o n
The association between the MTX peak levels and the outcome of osteosarcoma has been a matter of debate. Several studies have reported superior outcomes with using higher MTX doses rather than lower doses, and the MTX peak level was considered to be related with the histologic response 5, 7) . Because of the limited number of patients and the heterogeneity of the study population, the previous studies have produced conflicting results. To more precisely assess the relationship between the MTX level and the outcome, we selected patients with localized osteosarcoma who have received more than 3 cycles of HD MTX before definitive surgery. A MTX peak level above 1,000 µM was achieved in most of our patients (82.4%). It is intriguing that the patients with a high MTX level (both the peak and 24-hr levels) showed a shorter event-free survival. However, we could not find any positive association between the MTX peak level and the histologic response. In contrast, the 24-hr MTX level showed inverse correlation with the histologic response;
that is, patients with a high 24-hr MTX level showed a poor histologic response.
Although this was a single-institution study, it has several limitations. First, this was a retrospective study and the patients were not randomized or controlled with respect to the treatment protocols, including the chemotherapeutic regimens and the type of operation. Second, the study population was small and the follow-up periods were not long enough. Last, we were not able to present detailed data about the pharmacokinetics of MTX, since the required software programs were not available in our institution.
The serum level of MTX is supposed to represent the drug concentration in tumor cells 5, 9) . Therefore, it is conceivable that a high serum MTX concentration might result in better tumor cell necrosis and possibly a good prognosis. However, this assumption might only be relevant when MTX plays a dominant role in killing tumor cells. In the era of combination chemotherapy, all the employed drugs play concerted roles in tumor cell necrosis 16) . Accordingly, the correlation between the MTX level and the histologic response is likely to be dependent on MTX's contribution to tumor cell necrosis. We reviewed previous studies, especially in the context of the proportion of MTX that was used in each protocol. We calculated the proportion of MTX using following simple formula: the number of MTX adminstrations/ total number of administrations for all the drugs used in preoperative chemotherapy. For example, the proportion of MTX would be 100% in the MTX monodrug protocol. Delepine et al. 5) and
Saeter et al. 7) who adopted the monodrug protocol, consistently found a close relationship between the MTX peak level and the histologic response 5, 7) . In the COSS-80 protocol, which was comprised of 4 courses of HD MTX and one course of both doxorubicin and cisplatin, the proportion of MTX was calculated as 67% (4/4+1+1) 9) . In this study, the MTX peak level ≥1,000 µM was related to a good histologic response. Contrastingly, in the successive COSS protocols and other trials, the proportion of MTX ranged from 28.6% to 50% and relationship between the MTX peak level and the histologic response was not found [9] [10] [11] . In the current study, the proportion of MTX was 50%. Our contradictory results (the inverse correlation between the MTX level and the outcome or the necrotic rate) were unexpected. Only one previous study supported our results 12) . These findings are counterintuitive and the causative mechanism for this association is unclear. One possibility is that an increased leucovorin dose in patients with very high peak and 24-hr . Further studies are needed to clarify the optimal dose of leucovorin and its influence on tumor cells. Another possible explanation is that prolonged exposure to a high MTX concentration resulted in delayed delivery of the scheduled chemotherapy, thus reducing the intensity. In the present study, we evaluated the possible correlation between the MTX level and delay in the chemotherapy schedule. However, no correlation was found, since renal function was not impaired and delivery of next chemotherapy was not significantly delayed in patients with a high peak and 24-hr MTX levels (data not shown). Lastly, abnormal MTX pharmacokinetics may influence on the metabolism of other chemotherapeutic agents such as doxorubicin and cisplatin. CYP 3A4 isoenzyme family mediates the pharmacokinetic variability of doxorubicin [18] [19] [20] . A recent study reported that a high CYP3A4/5 expression in osteosarcoma cells could predict metastasis and poor prognosis 21) . At present, there is a limited evidence for drug interaction between MTX and doxorubicin; however, we presume that future studies concerned with the association between the pharmacokinetics and drug metabolism of MTX would give us some clues.
In conclusion, the patients with a high MTX level showed a shorter event-free interval and a poor histologic response.
Further study about the pharmacokinetics of MTX is man-
